Cigna vs Cvs Health
CI and CVS side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CI and CVS compare
Cvs Health is the larger company, worth 1.4 times as much as Cigna ($114B against $79.7B).
On earnings, Cvs Health is cheaper: it trades at 10.4× trailing earnings, against 13.3× for Cigna.
Cigna grew revenue faster over the last twelve months (6.8% versus 6.7% for Cvs Health).
Cvs Health keeps more of each dollar of sales as profit, with a net margin of 2.6% compared with 2.1% at Cigna.
Both pay dividends: Cigna yields 2.1% and Cvs Health 2.2%.
Cvs Health scores higher on the StockData Score (19 against 16 for Cigna), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CI | CVS |
|---|---|---|
| Size and price | ||
| Market cap | $79.7B | $114B |
| Share price | $301.45 | $89.52 |
| Change, 1 year | 16.8% | 15.5% |
| Change, 5 years | 43.2% | −3.9% |
| Beta (5Y) | 0.34 | 0.50 |
| Employees | 68K | 300K |
| StockData Score | ||
| Total score | 16 | 19 (better) |
| Valuation score | 6 | 6 |
| Growth score | 2 | 3 (better) |
| Performance score | 3 | 4 (better) |
| Health score | 2 | 2 |
| Dividend score | 3 | 4 (better) |
| Valuation | ||
| P/E | 13.3× | 10.4× (better) |
| P/S | 0.3× | 0.3× (better) |
| P/B | 1.8× | 1.4× (better) |
| EV/EBITDA | 8.2× | 8.2× (better) |
| P/FCF | – | 7.4× |
| PEG | 11.23 | – |
| FCF yield | – | 13.6% |
| Fair value | $383.88 | $129.23 |
| Margin of safety | 21.5% | 30.7% (better) |
| Growth | ||
| Revenue growth (TTM) | 6.8% (better) | 6.7% |
| Revenue growth, 5Y average | 11.4% (better) | 8.4% |
| Net income growth (TTM) | – | 2253% |
| EPS growth (TTM) | −0.04% | 2158% (better) |
| EPS growth, 5Y average | −0.69% (better) | −23.9% |
| Profitability | ||
| Gross margin | 20.7% | 44.2% (better) |
| Operating margin | 3.4% | 3.6% (better) |
| Net margin | 2.1% | 2.6% (better) |
| FCF margin | – | 3.7% |
| Return on equity | 14.1% | 14.4% (better) |
| Return on invested capital | 11.4% (better) | 10.8% |
| Financial health | ||
| Debt / equity | 0.72 (better) | 0.75 |
| Net debt / EBITDA | 1.88 (better) | 2.34 |
| Interest coverage | 7.1× (better) | 4.9× |
| Current ratio | 0.84 | 0.85 (better) |
| Altman Z-score | 2.83 (better) | 2.51 |
| Piotroski F-score | 7 | 7 |
| Dividends and buybacks | ||
| Dividend yield | 2.1% | 2.2% (better) |
| Payout ratio | 27.2% | 31.0% |
| Years of dividend growth | 5 (better) | 0 |
| Dividend growth, 5Y average | 173% (better) | 5.9% |
| Buyback yield | 1.7% | – |
| Shareholder yield | 3.7% (better) | 2.2% |
| Ownership | ||
| Held by institutions | 89.9% | 89.2% |
| Held by insiders | 0.41% | 0.43% |
| Insider net buying, 12 months | −$66.8M (better) | −$322M |
| Superinvestors holding | 4 | 6 (better) |
| Short interest, % of float | 2.4% | 1.4% |
Go deeper
- CI stock overview
- CI income statement
- CI valuation and score
- CVS stock overview
- CVS income statement
- CVS valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.